摘要
MutS同源物6(MutS homolog 6,MSH6)基因是一种错配修复(mismatch repair,MMR)基因,其编码的MSH6蛋白主要参与识别、修复碱基取代和单碱基插入/缺失错配。MSH6基因种系突变增加胶质瘤的肿瘤易感性,体细胞MSH6基因突变可致烷化剂的获得性耐药和胶质瘤复发,MSH6突变可导致基因组的超突变从而促进胶质瘤的进展。最新研究亦发现MSH6基因存在致癌作用,其上调将导致预后不佳。
MSH6 is a component of the MMR system,encoded MSH6 protein that is mainly involved in identifying nucleotides incorporation,insertion or deletion.Germline MSH6 mutations cause an increasing opportunity for glioma.Somatic mutations of MSH6,most likely result from TMZ treatment,are not in connection with susceptibility to glioma but associated with the resistance to TMZ.Hypermutations occurring in the genome of glioma cells possibly accelerate its deteriorating progress.A study suggested that the up-regulated of MSH6 was related to the miserable prognosis in glioma patients and the carcinogenesis.
作者
石莹
崔英哲
刘鹏飞
Shi Ying;Cui Yingzhe;Liu Pengfei(Department of Magnetic Resonance,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000,China)
出处
《现代肿瘤医学》
CAS
2020年第20期3617-3619,共3页
Journal of Modern Oncology
基金
国家自然科学基金面上项目(编号:81771894)。
关键词
MSH6
胶质瘤
突变
耐药
MSH6
glioma
mutation
chemotherapy-resistance
